TREACE MEDICAL CONCEPTS, INC. (TMCI): Price and Financial Metrics Recent IPO


TREACE MEDICAL CONCEPTS, INC. (TMCI): $28.98

0.95 (+3.39%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

TMCI Stock Price Chart Interactive Chart >

Price chart for TMCI

TMCI Price/Volume Stats

Current price $28.98 52-week high $37.17
Prev. close $28.03 52-week low $22.46
Day low $27.68 Volume 336,100
Day high $29.23 Avg. volume 238,630
50-day MA $27.16 Dividend yield N/A
200-day MA $0.00 Market Cap 1.53B

TREACE MEDICAL CONCEPTS, INC. (TMCI) Company Bio


Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of device and/or biologic solutions for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was incorporated in 2014 and is headquartered in Ponte Vedra Beach, Florida.


TMCI Latest News Stream


Event/Time News Detail
Loading, please wait...

TMCI Latest Social Stream


Loading social stream, please wait...

View Full TMCI Social Stream

Latest TMCI News From Around the Web

Below are the latest news stories about Treace Medical Concepts Inc that investors may wish to consider to help them evaluate TMCI as an investment opportunity.

Treace Announces Launch of Adductoplasty™ Instrumented Midfoot Correction System

PONTE VEDRA, Fla., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, today announced the commercial launch of the Adductoplasty™ System. The Adductoplasty™ System brings together Treace’s implants and precision instrumentation for the first comprehens

Yahoo | September 13, 2021

Treace Announces Participation in the Morgan Stanley 19th Annual Global Healthcare Conference

PONTE VEDRA, Fla., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, today announced that John T. Treace, Chief Executive Officer, and Mark Hair, Chief Financial Officer, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Gl

Yahoo | September 2, 2021

Treace Announces New Supportive ALIGN3D™ Data to be Presented at the 2021 AOFAS Annual Meeting

PONTE VEDRA, Fla., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, today announced the upcoming presentation of new data at the 2021 American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting to be held September 22-25 in Charlotte, North Caro

Yahoo | September 1, 2021

Treace Medical Concepts, Inc. (TMCI) Q2 2021 Earnings Call Transcript

After the speakers' presentation, there will be a question-and-answer session [Operator instructions] Please be advised that today's conference is being recorded via webcast. Participating from the company today will be John Treace, chief executive officer; and Mark Hair, chief financial officer.

Yahoo | August 8, 2021

Treace Medical Concepts Reports Second Quarter 2021 Financial Results

PONTE VEDRA, Fla., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today reported financial results for the second quarter ended June 30, 2021. Recent Highlights: Revenue of $20.7 million, a 167% increase over the same period last yearGross margin of 80.9%, an increase of 780 basis poin

Yahoo | August 5, 2021

Read More 'TMCI' Stories Here

TMCI Price Returns

1-mo 18.24%
3-mo -13.44%
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7111 seconds.